Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke

Neuropathology and Applied Neurobiology

Volumn 23, Issue 5, 1997, Pages 406-415

  Anthony, D C ^a   Ferguson, B ^a   Matyzak, M K ^a   Miller, K M ^b   Esiri, M M ^c   Perry, V H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Blood brain barrier; Metalloproteinase; Multiple sclerosis; Stroke

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE MIGRATION; MACROPHAGE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE;

EID: 0030800573     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.1997.tb01315.x     Document Type: Article

References (47)

1. Anthony DC, Savage FJ, Hembry RM, Boulos PB. Protease activity in experimental colitis. Agents Actions 1994; 41: C201-3
2. Bailey C. 1992. Collagen Metabolism in Crohn's Disease. PhD thesis, University of Manchester
3. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-65
4. Chandler S, Coates R, Gearing A et al. Matrix metalloproteinases degrade myelin basic-protein. Neurosci Letts 1995; 201: 223-6
5. Clements JM, Cossins JA, Wells GMA et al. Matrix metalloproteinase expression during experimental autoimmune tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997; 74: 85-94
6. Conway JG, Wakefield JA, Brown RH et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Experiment Med 1995; 182: 449-57
7. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen-activator, matrix metalloproteases and endogenous inhibitors in the central-nervous- system in multiple-sclerosis-comparison of stages in lesion evolution. J Neuropath Experiment Neurol 1996; 55: 1194-204
8. Delclaux C, Delacourt C, Dortho MP et al. Role of gelatinase-B and elastase in human polymorphonuclear neutrophil migration across basement-membrane. Am J Respir Cell Mol Biol 1996; 14: 288-95
9. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth-factors and cytokines of 95-kDa and 72-kDa gelatinases and tissue inhibitors of metalloproteinase-1, metalloproteinase-2 and metalloproteinase-3 in rabbit aortic smooth-muscle cells. Biochem J 1996; 315: 535-42
10. Gay D, Esiri M. Blood-brain-barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991; 114: 557-72
11. Gearing AJH, Beckett P, Christodoulou M et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukocyte Biol 1995; 57: 774-7
12. Gijbels K, Galardy RF, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Investigation 1994; 94: 2177-82
13. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34
14. Gijbels K, Proost P, Masure S et al. Gelatinase-B is present in the cerebrospinal-fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic-protein. J Neurosic Res 1993; 36: 432-40
15. Halpert I, Sires UI, Roby JD et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Nat Acad Sci USA 1996; 93: 9748-53
16. Hembry RM, Bagga MR, Murphy G, Henderson B, Rynolds JJ. Rabbit models of arthritis: immunolocalisation of matrix metalloproteinases and tissue inhibitor of metalloproteinase in synovium and cartilage. Am J Pathol 1993; 143: 628-42
17. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult-mouse brain. Neurosic 1990; 39: 151-70
18. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Experiment Neurol 1996; 55: 300-9
19. Marier JR, Brott T, Broderick J et al. Tissue-plasminogen activator for acute ischemic stroke. New Eng J Med 1995; 333: 1581-7
20. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992; 14: 455-63
21. Matyszak M, Perry V. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 1996; 69: 141-9
22. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95
23. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987; 248: 265-8
24. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95kDa and 72kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277: 277-9
25. Murphy G, Hembry RM. Proteinases in rheumatoid-arthritis. J Rheumatol 1992; 19: 61-4
26. Murphy G, Reynolds J. Extracellular matrix degradation. In Connective Tissue and its Heritable Disorders, Eds P Royce and B Steinmann. New York: Wiley-Liss, 1993: 287-316
27. Nag S. Immunohistochemical localization of extracellular matrix proteins in cerebral vessels in chronic hypertension. J Neuropathol Experiment Neurol 1996; 55: 381-8
28. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama JI. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995; 83: 298-307
29. Opdenakker G, Van Damme J. Cytokines and proteases in invasive processes-molecular similarities between inflammation and cancer. Cytokine 1992; 4: 251-8
30. Paemen L, Olsson T, Soderstrom M, Vandamme J, Opdenakker G. Evaluation of gelatinases and Il-6 In the cerebrospinal-fluid of patients with optic neuritis, multiple-sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994; 1: 55-63
31. Polette M, Clavel C, Cockett M et al. Detection and localization of messenger-RNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993; 13: 31-7
32. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase-B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Comm 1993; 192: 1175-81
33. Rao JS, Steck PA, Mohanam S et al. Elevated levels of M(r) 92 000 type IV collagenase in human brain tumors. Cancer Res 1993; 53: 2208-11
34. Rao JS, Yamamoto M, Mohaman S et al. Expression and localization of 92kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Experiment Metastasis 1996; 14: 12-18
35. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994; 125: 1165-78
36. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12: 833-42
37. Rosenberg GA, Dencoff JE, Correa NJr, Heiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain-barrier injury. Neurol 1996; 46: 1626-32
38. Rosenberg GA, Estrada EY, Dencoff JE, Stetlerstevenson WG. Tumor necrosis factor-alpha-induced gelatinase-B causes delayed opening of the blood-brain-barrier-an expanded therapeutic window. Brain Res 1995; 703: 151-5
39. Rosenberg GA, Kornfeld M, Estrada E et al. TIMP-2 reduces proteolytic opening of blood-brain-barrier by type IV collagenase. Brain Res 1992; 576: 203-7
40. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cerebral Blood Flow Metab 1996; 16: 360-6
41. Ruoslahti E. Brain extracellular-matrix. Glycobiol 1996; 6: 489-92
42. Sawaya RE, Yamamoto M, Gokaslan ZL et al. Expression and localization of 72kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Experiment Metastasis 1996; 14: 35-42
43. Sherriff FE, Bridges LR, Jackson P. Microwave antigen retrieval of beta-amyloid precursor protein immunoreactivity. Neuroreport 1994; 5: 1085-8
44. Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996; 39: 1255-64
45. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384: 123-4
46. Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72kDa progelatinase complex. Demonstration of the biochemical similarities oftissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem J 1991; 278: 179-87
47. Yamada T, Yoshiyama Y, Sato H et al. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol 1995; 90: 421-4